Program
Axitinib
Also written as “AG-013736”, “axitinib” and “OTX-TKI”.
Its studies are mostly in Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Macular Degeneration · Neoplasms · Carcinoma, led by 6 companies.
Drug pageAxitinib: every studyMany companies study it; this page follows only the 45 they lead. All 139 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 360 open or running | phase 3since May 7, 2007 | Oct 9, 2003 | none ahead |
| Ocular Therapeutixits history only | 54 open or running | phase 3since Jan 12, 2024 | Jun 1, 2018 | Jan 8, 2027phase 3 · NCT06495918 |
| Arog Pharmaceuticalsits history only | 10 open or running | phase 2since Oct 6, 2006 | Oct 6, 2006 | none ahead |
| Merckits history only | 10 open or running | phase 3since Jul 29, 2016 | Jul 29, 2016 | none ahead |
| SFJ Pharma Ltd. IIits history only | 10 open or running | phase 3since May 11, 2012 | May 11, 2012 | none ahead |
| Strata Oncologyits history only | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Fortrea, Gilead Sciences and SFJ Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 31 studies since Oct 9, 2003.
- Nov 2, 2011Phase 1 study in Advanced Solid TumorsPfizer · NCT01469052 · 36 enrolled · United States
- May 11, 2012SFJ Pharma Ltd. II’s first study: phase 3 study in Carcinoma, Renal CellNew to SFJ Pharma Ltd. IISFJ Pharma Ltd. II · NCT01599754 · 724 enrolled · United States, China, France and more
- Nov 26, 2013Phase 1 study in CarcinomaPfizer · NCT01999972 · 50 enrolled · United States, United Kingdom
- May 6, 2014Phase 1 study in Carcinoma, Renal CellPfizer · NCT02133742 · 52 enrolled · United States
- Jan 25, 2016Phase 3 study in Carcinoma, Renal CellPfizer · NCT02684006 · 886 enrolled · United States, Australia, Austria and more
- Jul 29, 2016Merck’s first study: phase 3 study in Carcinoma, Renal CellNew to MerckMerck · NCT02853331 · 861 enrolled
- Aug 28, 2017Phase 1 study in Carcinoma, HepatocellularPfizer · NCT03289533 · 22 enrolled · Japan
- Feb 28, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03472560 · 61 enrolled · United States, Hungary, Italy and more
- Jun 1, 2018Ocular Therapeutix’s first study: phase 1 study in Neovascular Age-related Macular DegenerationNew to Ocular TherapeutixOcular Therapeutix · NCT03630315 · 29 enrolled · Australia
- Oct 1, 2021Strata Oncology’s first study: phase 2 study in NeoplasmsNew to Strata OncologyStrata Oncology · NCT05097599 · 11 enrolled · United States
- Jan 5, 2023Phase 1 study in Non-proliferative Diabetic RetinopathyOcular Therapeutix · NCT05695417 · 21 enrolled · United States
- Jan 12, 2024Phase 3 study in Neovascular Age-Related Macular DegenerationOcular Therapeutix · NCT06223958 · 344 enrolled · United States, Argentina, Puerto Rico
- Jul 3, 2024Phase 3 study in Neovascular Age-related Macular DegenerationOcular Therapeutix · NCT06495918 · 825 enrolled · United States, Argentina, Australia and more
- Mar 31, 2026Phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)Ocular Therapeutix · NCT07516132 · 850 planned · United States
Ahead
- Jan 8, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationOcular Therapeutix · NCT06495918
- Aug 1, 2030Primary completion: phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)Ocular Therapeutix · NCT07516132
TargetBeta
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
Studies
All 45 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07516132Neovascular Age-Related Macular Degeneration (nAMD) · United States | 3 | Recruiting | Ocular Therapeutix | Aug 1, 2030 | 850 |
| NCT06495918Neovascular Age-related Macular Degeneration · United States, Argentina, Australia and more | 3 | Active, not recruiting | Ocular Therapeutix | Jan 8, 2027 | 825 |
| NCT06223958Neovascular Age-Related Macular Degeneration · United States, Argentina, Puerto Rico | 3 | Active, not recruiting | Ocular Therapeutix | Apr 29, 2026 | 344 |
| NCT05695417Non-proliferative Diabetic Retinopathy · United States | 1 | Active, not recruiting | Ocular Therapeutix | Jan 2024 | 21 |
| NCT05097599Neoplasms · United States | 2 | Terminated | Strata Oncology | Jun 12, 2024 | 11 |
| NCT03630315Neovascular Age-related Macular Degeneration · Australia | 1 | Completed | Ocular Therapeutix | Jan 10, 2024 | 29 |
| NCT03472560Carcinoma, Non-Small-Cell Lung · United States, Hungary, Italy and more | 2 | Terminated | Pfizer | Feb 9, 2023 | 61 |
| NCT03289533Carcinoma, Hepatocellular · Japan | 1 | Completed | Pfizer | Aug 27, 2019 | 22 |
| NCT02853331Carcinoma, Renal Cell | 3 | Completed | Merck | Oct 18, 2018 | 861 |
| NCT02684006Carcinoma, Renal Cell · United States, Australia, Austria and more | 3 | Completed | Pfizer | Aug 31, 2023 | 886 |
| NCT02133742Carcinoma, Renal Cell · United States | 1 | Completed | Pfizer | Mar 31, 2017 | 52 |
| NCT01999972Carcinoma · United States, United Kingdom | 1 | Completed | Pfizer | Feb 22, 2017 | 50 |
| NCT01599754Carcinoma, Renal Cell · United States, China, France and more | 3 | Terminated | SFJ Pharma Ltd. II | Oct 10, 2017 | 724 |
| NCT01469052Advanced Solid Tumors · United States | 1 | Completed | Pfizer | Jul 2004 | 36 |
| NCT01441388Carcinoma, Renal Cell | 1 | Withdrawn | Pfizer | Nov 2013 | 0 |
| NCT01210495Carcinoma, Hepatocellular · United States, Belgium, China and more | 2 | Completed | Pfizer | Mar 3, 2014 | 224 |
| NCT01020136Healthy Volunteer · Singapore | 1 | Completed | Pfizer | Feb 2010 | 42 |
| NCT00920816Kidney Neoplasms · United States, Bosnia and Herzegovina, Bulgaria and more | 3 | Completed | Pfizer | Jul 27, 2012 | 492 |
| NCT00919204Healthy Volunteers · China | 1 | Completed | Pfizer | Aug 2009 | 14 |
| NCT00918632Healthy Volunteers · Belgium | 1 | Completed | Pfizer | Jul 2009 | 30 |
| NCT00905814Healthy Volunteers · Singapore | 1 | Completed | Pfizer | Sep 2009 | 60 |
| NCT00842244Stomach Neoplasms · Japan, Korea, Republic of | 1 | Completed | Pfizer | Dec 2009 | 22 |
| NCT00835978Carcinoma, Renal Cell · United States, Czechia, Germany and more | 2 | Completed | Pfizer | Oct 2012 | 213 |
| NCT00828919Solid Tumors · United States, Czechia, France and more | – | Completed | Pfizer | Aug 14, 2023 | 52 |
| NCT00768755Carcinoma, Non-Small-Cell Lung · United States, Italy, Japan and more | 2 | Completed | Pfizer | Mar 2011 | 180 |
| NCT00735904Carcinoma · Poland, Romania, South Africa and more | 2 | Completed | Pfizer | Nov 2011 | 38 |
| NCT00726752Neoplasms · Japan | 1 | Completed | Pfizer | Apr 2010 | 6 |
| NCT00692341Hepatic Insufficiency · United States | 1 | Completed | Pfizer | Oct 2008 | 24 |
| NCT00678392Kidney Neoplasms · United States, Australia, Austria and more | 3 | Completed | Pfizer | Aug 31, 2010 | 723 |
| NCT00615056Colorectal Neoplasms · United States, Canada, France and more | 2 | Completed | Pfizer | Mar 2011 | 171 |
| NCT00600821Carcinoma, Non-Small-Cell Lung · United States, Czech Republic, France and more | 2 | Completed | Pfizer | Apr 2011 | 118 |
| NCT00569946Carcinoma, Renal Cell · Japan | 2 | Completed | Pfizer | Feb 26, 2010 | 64 |
| NCT00471146Carcinoma, Pancreatic Ductal · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Jan 2009 | 630 |
| NCT00460603Colorectal Neoplasms · United States | 2 | Completed | Pfizer | Apr 2012 | 187 |
| NCT00454649Neoplasms · United States, Poland, Spain | 1 | Completed | Pfizer | Aug 2009 | 102 |
| NCT00447005Carcinoma · Japan | 1 | Completed | Pfizer | Aug 2009 | 12 |
| NCT00389441Thyroid Neoplasms · United States, Canada, China and more | 2 | Completed | Pfizer | Sep 2012 | 52 |
| NCT00386555Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Arog Pharmaceuticals | 0 | |
| NCT00282048Kidney Neoplasms · United States | 2 | Completed | Pfizer | Feb 2009 | 62 |
| NCT00219557Pancreatic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Mar 14, 2008 | 111 |
| NCT00094107Melanoma · United States, France | 2 | Completed | Pfizer | Apr 2008 | 32 |
| NCT00094094Lung Neoplasms · United States, Germany | 2 | Completed | Pfizer | Jul 2007 | 32 |
| NCT00094055Thyroid Neoplasms · United States | 2 | Completed | Pfizer | Jan 2009 | 60 |
| NCT00076024Breast Neoplasms · United States, Canada, Czech Republic and more | 2 | Completed | Pfizer | Jan 2007 | 174 |
| NCT00071006Leukemia, Myeloid, Acute · United States | 2 | Completed | Pfizer | Jul 2004 | 12 |
How it is read
Names in the registry
- “AG-013736”, 23 entries
- “axitinib”, 13 entries
- “OTX-TKI”, 8 entries
- “Axitinib (AG-013736)”, 8 entries
- “AG-013736 (axitinib)”, 7 entries
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 8 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Macular Degeneration, 4 studies
- Neoplasms, 3 studies
- Carcinoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.